Korro Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Korro Bio, Inc. (KRRO) on December 18, 2025, covering events occurring on December 15, 2025. The filing addresses Item 5.02 regarding the amendment of an executive employment agreement.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation adjustments.
Material Changes
Effective December 15, 2025, Korro Bio entered into an amended and restated employment agreement with Jeffrey Cerio. Key changes include:
- Base Salary: Increased to $425,000 annually.
- Severance (Standard): Increased from six months to nine months of salary for termination without cause or resignation for good reason.
- Severance (Change in Control): Increased from nine months to 12 months of salary for qualifying terminations within the change in control period.
- Cash Bonus: Awarded a $100,000 bonus, payable in two installments (50% on December 31, 2025, and 50% on or about June 30, 2026), contingent on continuous service.
- Equity Award: Granted 41,902 Restricted Stock Units (RSUs) under the 2023 Stock Option and Incentive Plan, vesting 50% on June 15, 2026, and 50% on December 15, 2026, contingent on continuous service.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of general business risks. The primary contingency noted is the requirement for Dr. Cerio to maintain continuous service to receive the cash bonus and equity vesting.
Investor Verification Checklist
- Verify the total cash outflow impact of the $100,000 bonus and increased salary on the company's cash position.
- Review the full text of the Amended and Restated Employment Agreement (Exhibit 10.1) for specific definitions of "good reason" and "change in control."
- Assess the dilution impact of the 41,902 RSUs granted to Dr. Cerio.
- Confirm the company's current cash runway given the increased fixed compensation costs.